Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381906 | 0.89 | CETP (0.37) | CETPCPB2 | |
| SCHEMBL6383166 | 0.88 | CETP (0.37) | CETP | |
| SCHEMBL6381319 | 0.86 | CETP (0.39) | CETP | |
| SCHEMBL6386119 | 0.85 | FFAR3 (0.34) | CETPFFAR3CYP2C19RXRA | |
| SCHEMBL6382992 | 0.76 | HDAC1 (0.33) | FFAR3 | |
| SCHEMBL14127769 | 0.76 | CETP (0.33) | CETPPOLBCPB2CYP2C19 | |
| SCHEMBL3153596 | 0.75 | — | — | |
| SCHEMBL8376359 | 0.75 | CPB2 (0.30) | CPB2 | |
| Hydrochloric Acid SCHEMBL11613521 | 0.73 | CYP2C19 (0.38) | CETPFFAR3CPB2CYP2C19 | |
| SCHEMBL4277564 | 0.71 | CYP2C19 (0.52) | CETPFFAR3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113447-A1 | Selective retinoid agonists | BELLONI PAULA N (US) | 2005-05-26 | — | — | US | disclosed |
| US-6828337-B2 | Bicyclic retinods containing ester or acid group; useful for treating emphysema | HOFFMANN-LA ROCHE INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1206436-B1 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | HOFFMANN LA ROCHE (CH) | 2004-10-13 | — | — | EP | disclosed |
| US-20030176726-A1 | Bicyclic retinods containing ester or acid group; useful for treating emphysema | HOFFMANN-LA ROCHE INC. | 2003-09-18 | — | — | US | disclosed |
| US-6528677-B1 | Such as 4-(4,4,7,7-tetramethyl-2-pentyl-2,3,4,5,6,7-hexa-hydro-1H-indene-2 -ylethynyl)-benzoic acid; emphysema | HOFFMANN-LA ROCHE INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1206436-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001009076-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176726-A1 | Bicyclic retinods containing ester or acid group; useful for treating emphysema | RARG, RXRA, RXRG | CETP 634/4885FFAR3 136/4885POLB 1451/4885 |
| US-20050113447-A1 | Selective retinoid agonists | RARA, RARB, RARG | CETP 1857/4885FFAR3 53/4885POLB 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.